Adaptimmune Therapeutics Plc Цена / балансовая стоимость
Что обозначает Цена / балансовая стоимость в Adaptimmune Therapeutics Plc?
Цена / балансовая стоимость Adaptimmune Therapeutics Plc является 5.72
Какое определение для Цена / балансовая стоимость?
Отношение рыночной цены акции к её балансовой учётной стоимости представляет собой соотношение между стоимостью акций компании и балансовой стоимостью на акцию.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Цена / балансовая стоимость компаний в Health Care сектор на NASDAQ по сравнению с Adaptimmune Therapeutics Plc
Что делает Adaptimmune Therapeutics Plc?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Компании с цена / балансовая стоимость похож на Adaptimmune Therapeutics Plc
- Miragen Therapeutics Inc имеет Цена / балансовая стоимость из 5.71
- Aeeris имеет Цена / балансовая стоимость из 5.71
- AusNet Services Ltd имеет Цена / балансовая стоимость из 5.71
- Teradyne имеет Цена / балансовая стоимость из 5.71
- NIO Inc имеет Цена / балансовая стоимость из 5.71
- Solid Biosciences Inc имеет Цена / балансовая стоимость из 5.72
- Adaptimmune Therapeutics Plc имеет Цена / балансовая стоимость из 5.72
- STADA Arzneimittel Aktiengesellschaft имеет Цена / балансовая стоимость из 5.72
- Amlogic (Shanghai) Co имеет Цена / балансовая стоимость из 5.72
- La Forestiere Equatoriale SA имеет Цена / балансовая стоимость из 5.72
- Palred Technologies имеет Цена / балансовая стоимость из 5.72
- The Hi-Tech Gears имеет Цена / балансовая стоимость из 5.73
- Renren Inc имеет Цена / балансовая стоимость из 5.73